HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients.

Darren J WongM LittlejohnL YuenK JacksonH MasonJ BaylissG RosenbergA GaggarK KitrinosM SubramanianP MarcellinM ButiH L A JanssenE GaneS LocarniniA ThompsonP A Revill

Published in: Alimentary pharmacology & therapeutics (2017)

Decline in HBeAg levels by week 24 was associated with HBeAg seroconversion and HBsAg loss in HBeAg-positive chronic hepatitis B patients treated with long-term TDF.

Keyphrases

hepatitis b virus
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
patient reported outcomes
placebo controlled